TY - JOUR
T1 - The Chicago Consensus on peritoneal surface malignancies
T2 - Management of peritoneal mesothelioma
AU - Chicago Consensus Working Group
AU - Schuitevoerder, Darryl
AU - Izquierdo, Francisco J.
AU - Plana, Alejandro
AU - Nash, Garrett M.
AU - Fernandez, Leopoldo J.
AU - Kluger, Michael D.
AU - Mack, Lloyd A.
AU - Mammen, Joshua M.V.
AU - Pameijer, Colette R.
AU - Polanco, Patricio M.
AU - Sideris, Lucas
AU - Skitzki, Joseph
AU - Abbott, Daniel E.
AU - Abdel-Misih, Sherif
AU - Ahrendt, Steven A.
AU - Al-Kasspooles, Mazin
AU - Amersi, Farin
AU - Arrington, Amanda K.
AU - Badgwell, Brian
AU - Barone, Robert M.
AU - Baumgartner, Joel M.
AU - Berri, Richard N.
AU - Bijelic, Lana
AU - Blazer, Dan G.
AU - Bowne, Wilbur B.
AU - Komen Brown, Charles
AU - Catenacci, Daniel V.
AU - Chan, Carlos H.F.
AU - Chandler, Christopher S.
AU - Chapel, David B.
AU - Cho, Clifford S.
AU - Choudry, M. Haroon A.
AU - Clarke, Callisia N.
AU - Cusack, James C.
AU - Dachman, Abraham H.
AU - Deneve, Jeremiah L.
AU - Dineen, Sean P.
AU - Eng, Oliver S.
AU - Fleshman, James
AU - Clark Gamblin, T.
AU - Gangi, Alexandra
AU - Georgakis, Georgios V.
AU - Gilbert, Erin W.
AU - Goodman, Martin D.
AU - Govindarajan, Anand
AU - Grotz, Travis E.
AU - Gushchin, Vadim
AU - Hanna, Nader
AU - Harmath, Carla
AU - In, Haejin
N1 - Funding Information:
Garrett M. Nash reports nonfinancial support from Intuitive outside the submitted work. James C. Cusack reports grants from Lumicell, Inc, outside the submitted work. Carla Harmath serves on the medical advisory council of Accumen. Hedy Kindler reports personal fees and nonfinancial support from Inventiva, AstraZeneca, Boehringer Ingelheim, Merck, and Paredox; personal fees from Aldeyra Therapeutics, Bayer, Bristol‐Myers Squibb, Erytech, Five Prime Therapeutics, Ipsen Pharmaceuticals, Kyowa, and MedImmune; and funds to support clinical trials at her institution from Aduro, AstraZeneca, Bayer, Bristol‐Myers Squibb, Deciphera, GlaxoSmithKline, Lilly, Merck, MedImmune, Polaris, Verastem, and Blueprint, all outside the submitted work. Aytekin Oto reports grants from Philips Healthcare, Guerbet, and Profound Healthcare and serves as a medical advisory board member for Profound Healthcare, all outside the submitted work. Nita Ahuja reports grant funding from Cepheid and Astex, has served as a consultant to Ethicon, and has licensed methylation biomarkers to Cepheid. Jesus Esquivel reports personal fees from Eight Medical. The other authors made no disclosures.
Funding Information:
Funded by the Irving Harris Foundation and the University of Chicago.
Publisher Copyright:
© 2020 by the American Cancer Society and Society of Surgical Oncology
PY - 2020/6/1
Y1 - 2020/6/1
N2 - The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of peritoneal mesothelioma. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
AB - The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of peritoneal mesothelioma. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
KW - consensus
KW - mesothelioma
KW - neoplasm metastasis
KW - peritoneal neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85084574417&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084574417&partnerID=8YFLogxK
U2 - 10.1002/cncr.32870
DO - 10.1002/cncr.32870
M3 - Article
C2 - 32282077
AN - SCOPUS:85084574417
SN - 0008-543X
VL - 126
SP - 2547
EP - 2552
JO - Cancer
JF - Cancer
IS - 11
ER -
